The effects of short-term hormone replacement therapy on long-term bone mineral density

Climacteric

Volumn 10, Issue 3, 2007, Pages 257-263

  Middleton, E T ^a   Steel, S A ^a  

^a HULL ROYAL INFIRMARY   (United Kingdom)

Author keywords

Bone mineral density; Hormone replacement therapy; Perimenopause

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; PROGESTERONE;

ADULT; ARTICLE; BONE ATROPHY; BONE DENSITY; CONTROLLED STUDY; FEMALE; HIP; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; OSTEOLYSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPINE; TRANSDERMAL PATCH; TREATMENT DURATION; TREATMENT OUTCOME;

BONE DENSITY; CASE-CONTROL STUDIES; DENSITOMETRY, X-RAY; DRUG ADMINISTRATION SCHEDULE; ESTROGEN REPLACEMENT THERAPY; FEMALE; FEMUR NECK; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 34248584700     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130701370435     Document Type: Article

References (20)

1. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003;290:1729-38
2. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
3. Ott SM. Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005;90:1897-9
4. Greenspan SL, Emkey RD, Bone HG, et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137:875-83
5. Purdie DW, Steel SA, Howey S, Doherty SM. The technical and logistical feasibility of population densitometry using DXA and directed HRT intervention: a 2-year prospective study. Osteoporos Int 1996;6(Suppl 3):31-6
6. Steel SA, Albertazzi P, Howarth EM, Purdie DW. Factors affecting long-term adherence to hormone replacement therapy after screening for osteoporosis. Climacteric 2003;6:96-103
7. Bagger YZ, Tanko LB, Alexandersen P, et al. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 2004;34:728-35
8. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long Term Extension (FLEX). JAMA 2006;296:2927-38
9. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99
10. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 2006;7:508-14
11. Woo SB, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61
12. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-301
13. Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001;28:524-31
14. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609-17
15. Al-Shahi R, Vousden C, Warlow C. Bias from requiring explicit consent from all participants in observational research: prospective, population based study. BMJ 2005;33:942-5
16. Junghans C, Feder G, Hemingway H, Timmis A, Jones M. Recruiting patients to medical research: double blind randomised trial of 'optin' versus 'opt-out' strategies. BMJ 2005;331:940-2
17. Ravn P, Cizza G, Bjarnason NH, et al. Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. J Bone Miner Res 1999;14:1622-7
18. Law MR, Hackshaw AK. A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect. BMJ 1997;315:841-6
19. Jackson RD, Wactawski-Wende J, LaCroix AZ, et al. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the Women's Health Initiative randomized trial. J Bone Miner Res 2006;21:817-28
20. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12